Market Overview

UPDATE: Aegis Capital Downgrades Galectin Therapeutics

Related GALT
36 Biggest Movers From Friday
36 Biggest Movers From Yesterday
Galectin Therapeutics (GALT) Investor Presentation - Slideshow (Seeking Alpha)

In a note released Friday morning, Aegis Capital analyst Raghuram Selvaraju downgraded shares of Galectin Therapeutics (NASDAQ: GALT) from Buy to Hold.

The downgrade comes amid result concerns as to whether or not the company will be able to demonstrate clinical effectiveness of its lead drug candidate GR-MD-02. The concerns arose when the second cohort of its Phase 1b trial did not show the same indications of potential anti-fibrotic efficacy as the previous cohort.

Amid the Aegis downgrade, shares of have dropped more than seven percent.

Latest Ratings for GALT

Oct 2017Roth CapitalInitiates Coverage OnBuy
Oct 2017Seaport GlobalInitiates Coverage OnBuy
Mar 2017H.C. WainwrightUpgradesNeutralBuy

View More Analyst Ratings for GALT
View the Latest Analyst Ratings

Posted-In: Aegis Capital Raghuram SelvarajuAnalyst Color Downgrades Price Target Analyst Ratings Movers


Related Articles (GALT)

View Comments and Join the Discussion!